Barbara S. Gillespie（医学博士、MMS、FASN）
Dr. Gillespie, board-certified in nephrology, joined Labcorp in 2017 after over a decade of leadership experience at Quintiles, where she held a variety of positions. These duties included reporting directly to the Chief Medical and Scientific Officer and serving as Global Therapeutic Lead for Nephrology and North American Head of the U.S. Internal Medicine team.
Dr. Gillespie serves on the board of directors of the Kidney Health Initiative (a public-private partnership between the FDA and the American Society of Nephrology) as well as on the steering committee for the National Kidney Foundation (NKF) Chronic Kidney Disease Registry. She is also on the board of directors for Nephronet and the Cardio Renal Society of America, has served on several global work groups and advisory boards for academic and trial-related stakeholders (including NKF, NephCure, Kidney Disease Improving Global Outcomes, ISN, Patient-Centered Outcomes Research Institute/University of North Carolina and PREPARE-NS) and has presented in many global forums and renal conferences.
She is also a past associate medical director at a small local dialysis unit and a fellow of the American Society of Nephrology. Dr. Gillespie received board certification in internal medicine in 2004 and in nephrology in 2006 and 2015. She completed her internal medicine residency at University of North Carolina and her nephrology fellowship at Duke.
Dr. Ennis, board-certified in internal medicine and nephrology, joined Labcorp Diagnostics as a medical director in 2009. In this role, she led the development of Labcorp's suite of laboratory-based clinical decision support offerings, including chronic kidney disease, cardiovascular disease and diabetes. 2020年，她成为临床与数字解决方案医学总监，为徕博科面向客户的技术解决方案组合提供临床指导和监督，并带领一个临床医生团队为产品组合创建内容。 She provides subject-matter expertise for nephrology initiatives throughout the organization and serves as a Labcorp representative on the National Kidney Foundation Laboratory Engagement Committee.
Dr. Ennis is also a clinical associate professor of medicine in the section of nephrology at the University of Illinois at Chicago where she sees patients weekly, lectures and supervises medical trainees.除了这些职责外，她还从事慢性肾脏疾病的临床研究，撰写了多篇摘要和同行评审出版物。
Dr. Ennis earned her MD from the University of Pittsburgh School of Medicine and completed internal medicine residency and nephrology fellowship training at the University of Chicago Medical Center.她是美国医师协会的会员。
Katherine T. Landschulz，博士
Dr. Landschulz joined Labcorp Drug Development in 2010, after more than a decade as a scientist in discovery through translational medicine roles at Pfizer, Abbott and Eli Lilly. At Labcorp, Dr. Landschulz helped establish the exploratory biomarker laboratory, Translational Biomarker Solutions, and served as associate director of this team prior to joining the newly established Biomarker Solution Center in 2018.
As Renal Disease Therapeutic Area Lead for the Labcorp Biomarker Solution Center, Dr. Landschulz is responsible for the delivery of biomarker strategies for sponsor programs in renal disease indications (e.g., acute kidney injury, chronic/diabetic kidney disease). Dr. Landschulz serves as a consultant to sponsors and teams, advising on matters related to biomarker selection and strategy development, laboratory placement of testing, feasibility designs and overall guidance around translational and exploratory biomarker data in drug development. Landschulz博士还作为联络人，负责转交问题并帮助发起人与徕博科生物标记物科学家建立联系。 Finally, Dr. Landschulz participates in enterprise-wide assessments and the licensing and implementation of new laboratory biomarker and tests transitioning from clinical trial to clinical care utilization.
Dr. Landschulz received her BSc in genetics at the University of California, Davis and her PhD in genetics/biology from Johns Hopkins University.她在约翰霍普金斯大学和德克萨斯大学西南医学院完成了博士后研究，并在1997年加入生物制药行业。
- Acute kidney injury
- Diabetic kidney disease
- Chronic kidney disease and associated complications (e.g., hyperkalemia and hyperphosphatemia)
- Glomerular disease including focal segmental glomerulosclerosis, IgA nephropathy and lupus nephritis
- End-stage kidney disease: dialysis (and associated complications such as cardiovascular outcomes) and kidney transplant
- Rare renal diseases
- Renal devices
- Renal impairment
- Renal cell carcinoma
Develop new perspectives through proprietary data
优先处理患者病程及相关数据对于实现成功的试验至关重要。在徕博科，我们可以针对您的研究的特定适应症和患者群体，制定并应用相应的策略。 Starting with vast patient diagnostic data from Labcorp's database of longitudinal patient data and site-specific recruitment metrics from our Central Laboratory and clinical investigator database, we can:
- Design the most efficient trial by focusing on the highest enrolling countries and sites and eliminating nonperformers
- Identify patients meeting your inclusion criteria who are near clinical trial sites and connect them to your trial
- Fully inform your protocol design to maximize recruitment and save time and money
Comprehensive, multifunctional nephrology experience and expertise to deliver better outcomes
Whether your study is looking for a rare population, expecting aggressive enrollment timelines or operating in a highly competitive environment, Labcorp has the expertise, data and experience to support trial design, proactively mitigate risk and deliver results.